TGA provisionally approves Pfizer Australia Pty Ltd’s COVID-19 treatment nirmatrelvir + ritonavir (PAXLOVID) on January 18, 2022. “The decision has been made on the basis of short term efficacy and safety data”.
TGA provisionally approves Pfizer Australia Pty Ltd’s COVID-19 treatment nirmatrelvir + ritonavir (PAXLOVID) on January 18, 2022. “The decision has been made on the basis of short term efficacy and safety data”.